Related Experiment Video
Updated: Jan 10, 2026
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Pancreatic involvement and its prognostic impact in acute-on-chronic liver failure
Georg Kramer1, Vlad Taru2, Benedikt Simbrunner1
1Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Laboratory, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria; Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
Introduction And Objectives:
Acute-on-chronic liver failure (ACLF) in cirrhotic patients is marked by a multiorgan failure and high mortality. The role of the pancreas in ACLF is poorly understood. This study evaluated the prevalence, progression and prognostic impact of elevated lipase (eLIP) and amylase (eAMY) in ACLF.
Patients And Methods:
We retrospectively analyzed ACLF patients (EASL-CLIF criteria) at the Vienna General Hospital (11/2003-11/2022). eLIP and eAMY were defined as levels ≥3 times the upper limit of normal. Data were collected before ACLF onset, at diagnosis (D0), and on days 7 (D7), 28 (D28), and 90 (D90) post-diagnosis. Factors associated with eLIP were identified using univariable logistic regression, and survival was examined with uni- and adjusted multivariable Cox regression models.
Results:
Among 193 patients, D28 and D90 mortalities were 39.9% and 53.9%, respectively. At D0, lipase and (alpha-)amylase elevations were found in 43.5% and 50.2% of patients, with strong correlation (Spearman's rho: 0.687; p<0.001). eLIP was observed in 8.8% at D0 and 15.7% at D7. At D0, impaired circulation (MAP <70 mmHg, odds ratio [OR] 4.41; p=0.048) and kidney failure (OR 6.31; p=0.030) were linked to eLIP, and circulatory failure at D0 (OR 3.30; p=0.012) to D7 eLIP. Although D0 enzyme levels did not prognosticate mortality, eLIP at D7 independently predicted D28 (adjusted hazard ratio [aHR]: 2.15; p=0.031) and D90 mortality (aHR 2.14; p=0.011).
Conclusions:
Increased lipase and (alpha-)amylase levels are common in ACLF. Notably, lipase levels ≥3x ULN at ACLF-D7 predict mortality independent from liver function, suggesting a role in disease progression.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow